“It’s important we maintain control over the process to ensure we are meeting the highest standards of quality,” says cell therapy developer Orca as it announces a 100,000 square-foot plant. Orca Bio’s lead product, the cell therapy Orca-T, is in Phase III clinical trials for several of the most prevalent blood cancers. As such, the firm is looking beyond its clinical manufacturing site in Sacramento, California and is constructing a 100,000 square-foot commercial facility nearby with the capacity to manufacture…
